The development of new medicines for autoimmune diseases has brought Sitryx Therapeutics and Eli Lilly & Co. together in an exclusive research and licensing collaboration where the young British biotech will be responsible for drug discovery while the US pharma giant will foot the bill and eventually get commercial rights to the resulting therapies.
The five-year collaboration, announced on 31 March, will study up to four novel preclinical targets identified by Sitryx that could...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
